vimarsana.com
Home
Live Updates
Valneva Initiates Phase 1 Trial of Second-Generation Zika Va
Valneva Initiates Phase 1 Trial of Second-Generation Zika Va
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Saint-Herblain , March 26, 2024 – Valneva SE , a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the the safety and immunogenicity of VLA1601,...
Related Keywords
Israel ,
Mexico ,
Japan ,
Hong Kong ,
South Korea ,
Norway ,
Australia ,
United States ,
Canada ,
Liechtenstein ,
New Zealand ,
Singapore ,
Iceland ,
France ,
Republic Of Korea ,
America ,
Japanese ,
French ,
Juan Carlos Jaramillo ,
Joshua Drumm ,
Dynavax Technologies Corporation ,
Exchange Commission ,
World Health Organization ,
Access To Advanced Health Institute ,
Global Communications ,
Tropical Disease Priority Review Voucher Program ,
Pfizer ,
Euronext Paris ,
Drug Administration ,
Tropical Disease Priority Review Voucher ,
Advanced Health Institute ,
Chief Medical Officer ,
Southeast Asia ,
Pacific Islands ,
South America ,
Prescribing Information ,
European Investor ,
Global Investor Relations ,
Disease Priority Review Voucher Program ,
Emergent Biosolutions ,
Valneva Report Positive Phase ,
Their Vaccine Candidate Against ,
Zika Virus ,
Markets ,